Abstract
Introduction: We compared the efficacy and safety of standard heparin to that of low molecular weight heparin (Enoxaparin) in 100 hip replacement patients. Materials and methods: A total of 100 patients who underwent total hip replacement surgery were randomised to receive a study medication. Enoxaparin was administered to 50 patients (prophylaxis with subcutaneous injection of 40 mg of Enoxaparin daily was initiated 12 h preoperatively), and heparin (subcutaneous standard heparin initiated 8 h preoperatively on a dose of 5,000 IU and continued to 15,000 IU per day in three equal dosages every 8 h) was given to 50 patients. Each treatment was continued until the patients were discharged from the hospital. They were made to undergo lower extremity duplex ultrasonography for deep vein thrombosis before discharge and discontinued from medication if no pathology was found. The primary parameter to determine the efficacy was the prevalence of venous thromboembolic disease. The primary parameter to determine safety was the prevalence of major bleeding. Results: Two patients in the heparin group developed DVT, which was detected by routine duplex ultrasonography at the end of hospitalisation, and two patients in the exoparine group were detected with late DVT during the postoperative period of 6 weeks. Seven patients had minor and major bleeding in both the groups. Six patients in the heparin group discontinued from medication because of hepatic, renal dysfunctions, and serious discharges from the wound. Conclusion: Enoxaparin is as safe and as effective as standard heparin in total hip replacement surgery.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G (1996) Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 335(10):696–700
Ciccone WJ II, Fox PS, Neumyer M, Rubens D, Parrish WM (1998) Ultrasound surveillance for asymptomatic deep venous thrombosis after total joint replacement. J Bone Joint Surg 80-A(8):1167–1174
Colwell CW Jr, Spiro TE, Trowbridge AA, Stephens JW, Gardiner GA Jr, Ritter MA (1995) Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. Clin Orthop 321:19–27
Colwell CW, Collis DK, Paulson R, Mccutchen JW, Bigler GT, Lutz S (1999) Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. J Bone Joint Surgery 81-A(7):932–940
Coventry MB, Nolan DR, Bechenbaugh RB (1973) Delayed prophylactic anticoagulation: a study of results and complications in 2012 total hip arthroplasties. J Bone Joint Surg 55-A(10):1487–1492
Eduardo AS, Vincent DP, Nigel ES, Paul AL, David WM, Hollis P (2000) Recent advances in venous thromboembolic prophylaxis during and after total hip replacement. J Bone Joint Surg 82-A:2
Gallay S, Waddell JP, Cardella P, Morton J (1997) A short course of low-molecular-weight heparin to prevent deep venous thrombosis after elective total hip replacement. Can J Surg 40(2):119–123
Haake DA, Berkman SA (1989) Venous thromboembolic disease after hip surgery. Clin Orthop 242:212–231
Hawkins DW, Langley PC, Krueger KP (1997) Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. Am J Health Syst Pharm 54(10):1992–1994
Hooker JA, Lachiewicz PF, Kelley SS, Hill C (1999) Efficacy of prophylaxis against thromboembolism with intermittant pneumatic compression after primary and revision total hip arthroplasty. J Bone Joint Surg 81-A(5):690–696
Johnson RG Jr, Charnley J (1977) Pulmonary embolism and its prophylaxis following the charnley total hip replacement. Clin Orthop 127:123–132
Nilsson PE, Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlund U, Nicolas S, Nylander G (1997) The post-discharge prophylactic management of the orthopedic patient with low-molecular-weight heparin: enoxaparin. Orthopedics Feb 20(Suppl):22–25
Planes A, Samama MM, Lensing AW, Buller HR, Barre J, Vochelle N, Beau B (1999) Prevention of deep vein thrombosis after hip replacement-comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost 81(1):22–25
Sarmiento A, Gables C, Goswami DK (1999) Thromboembolic prophylaxis with use of aspirin, exercise, and graded elastic stockings or intermittent compression devices in patients managed with total hip arthroplasty. J Bone Joint Surg 81-A(3):339–346
Senaran H, Atilla B, Acaroglu E (2000). Deep venous thrombosis in orthopaedic surgery. Hacettepe J Orthop Surg 10(1):18–21
The TIFDED Study Group (1999) Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin. Haemostasis 29(6):310–317
Author information
Authors and Affiliations
Corresponding author
Additional information
Study conducted at Hacettepe University and Selçuk Universities Hospitals, Turkey. Funds were received in partial support of the study from Eczacıbaşı-Rhone Poulenc co. This study was presented at the European Hip Society, Bristol, UK, 1999.
Rights and permissions
About this article
Cite this article
Senaran, H., Acaroğlu, E., Özdemir, H.M. et al. Enoxaparin and heparin comparison of deep vein thrombosis prophylaxis in total hip replacement patients . Arch Orthop Trauma Surg 126, 1–5 (2006). https://doi.org/10.1007/s00402-005-0079-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00402-005-0079-0